SHANGHAI, Nov. 28, 2018 /PRNewswire/ — WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it received the 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a top-notch business research and consulting firm. WuXi was awarded for the second consecutive year.
The award is part of the Frost & Sullivan Best Practices Award series, which recognizes companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. WuXi has been recognized for its excellence in demonstrating innovation and strong growth performance over the years.
“Adherence to best practices in service delivery has allowed WuXi AppTec to provide timely results and enable clients to achieve drug R&D and manufacturing cost optimization,” said Sanjeev Kumar, Industry Analyst from Frost & Sullivan Transformational Health. “WuXi has succeeded in achieving consistent growth by aligning its growth strategies with changing market needs. The company’s focus on addressing customer demand, broad industry coverage, and capacity development through state-of-the-art facilities has enabled WuXi to maintain and expand its client base globally.”
“Thank you Frost & Sullivan for recognizing WuXi’s enabling platform we have been diligently building over the years,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s an honor to serve our innovative partners around the world and help expedite the discovery and development of better medicines for patients.”
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”
ROCHESTER, New York, Nov. 28, 2018 /PRNewswire/ — Health Care Originals (HCO) announces its strategic alliance with Healthport. HCO is a leading manufacturer of medical wearables that complement digital heath technology. This alliance equips Healthport to support the rapidly growing digital health landscape of Australia and New Zealand.
Healthport scours the world to identify pioneering wearable products and proudly works alongside startups or established innovative technology companies. Healthport’s partners are responsible for moulding some of the most cutting-edge technological advancements to develop life changing, wearable medical devices that enable greater control and independence for those faced with chronic health conditions. Healthport’s Management team have a long history working within the field of chronic health and are passionate about achieving positive outcomes for patients.
“The team at HCO were impressed by Healthport and their alignment not only around improved patient outcomes, but also the progression of healthcare monitoring from an office setting to the home. This transition to consumer-focused healthcare, wherein we provide consumers with the right information at the right time to positively impact and control their healthcare outcomes, is central to our view of the future of healthcare. The Healthport team had previous experience and a history of excellent execution in the delivery of technology and services that successfully bridged that gap and this made us very comfortable that they are the right partner for us,” said Jared Dwarika, Co-Founder of HCO.
“Health Care Originals (HCO) has the leading wearable for collecting and processing physiological data of the respiratory system. At Healthport we recognised early on that HCO’s ADAMM™ and ADAMM-RSM™- Real time Respiratory monitoring systems, are products with unparalleled ability to empower patients to independently monitor and respond to the needs of respiratory disease. Asthma is an example of one chronic respiratory disease where HCO’s technology can help. In Australia, we have the dubious honour of having one of the highest levels of Asthma in the world, with many patients requiring close supervision. Given the levels of respiratory disease in Australia, HCO’s ADAMM™ has the ability to dramatically reduce emergencies and increase independence for many thousands of patients. In achieving these aims, ADAMM™ also has the capacity to have a positive impact on the growing burden to the public health purse. We are looking forward to making that a reality for Australia and New Zealand,” said Brett Doyle, CEO of Healthport.
ABOUT HEALTH CARE ORIGINALS:
Health Care Originals (HCO),(www.healthcareoriginals.com),a WT Innovation World Cup winner, is recognized for its Breakthrough Innovation that integrates IoT technologies to empower everyone through improved understanding and management of their health and medical conditions. HCO’s current wearable solutions are optimized for respiratory system applications, providing revolutionary, actionable insight into illnesses like asthma and COPD, respiratory syndromes, research, health & safety and competitive sports. HCO is a resident company of the Johnson & Johnson Innovation JLABS @ NYC.
-Contributing to Prevent Peptic Ulcer and Gastric Cancer
PARIS, Nov. 27, 2018 /PRNewswire/ — Helicobacter pylori infection is a major public health issue affecting 60% of the world’s population with 90% of Peptic Ulcers attributed to and 80% of Gastric Cancers associated with Hp infection.
With the support of an international expert panel composed of Pr Javier Gisbert & Dr Adrian Mc Nicholl (Spain), Pr Francesco Franceschi (Italy), Pr Peter Malfertheiner (Germany) and methodologists, a new study has been carried out to assess different strategies for Helicobacter pylori infection diagnosis & eradication control.
The results have been presented by Dr Adrian McNicholl (Hospital Universitario de La Princesa, Madrid, Spain) at the XXXIstInternational Workshop on Helicobacter & Microbiota in Inflammation and Cancer in Kaunas (Lithuania) on 14thSeptember 2018 during a “State of the Art” session.
The study shows that a “Test & Treat strategy” including the use of Urea Breath Tests as recommended in Spain is as effective as carrying out an endoscopy alone and has shown to be cheaper and more cost-effective than the symptomatic treatment strategy to manage dyspeptic patients. This strategy also seems to be the most cost-effective to prevent gastric cancer.
Pr Javier Gisbert, (Hospital Universitario de La Princesa, Madrid, Spain) stated: “Althoughthis Test & Treatstrategy is incorporated in guidelinesinmultiple countries, the analysis of the European Hp registry covering more than 20,000 patients shows that it is not always implemented. We need to teach our colleagues to align clinical practice with guidelines and the results from this cost-effectiveness study is an excellent opportunity for this.“
Jean-Nicolas Vernin, President of Mayoly Spindler declared: “As a key player in the field of Helicobacter pylori infection management, Mayoly Spindler is very proud to support this project with the aim to improve the diagnostic and the management of patients with Hp infection and help prevent Peptic Ulcer and Gastric Cancer across the world.“
By increasing awareness from Health Authorities, insurers, physicians, pharmacists and patients on the need for early diagnosis and eradication of Hp infection, this study will contribute to develop efficient prevention programs against Peptic Ulcer and Gastric Cancer.
SHANGHAI, Nov. 27, 2018 /PRNewswire/ — On June 18-20, 2019, the InnoPack China 2019 hosted by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and UBM EMEA and co-sponsored by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. (UBM Sinoexpo) will present an industrial event integrated with “product display”, “innovation activities”, and “high-end summits” to researchers and purchasers of the pharmaceutical industry in Hall N5 of Shanghai New International Expo Centre in Pudong. The exhibition will join hands with over 200 enterprises producing and designing pharmaceutical packaging materials and drug delivery devices. In only 3 days, every participant will be able to get all the latest product information they need.
P-MEC Layout
Area of zones is expanded year by year;global enterprises are attracted because of the specialties
As an unmissable annual industry event in the pharmaceutical packaging field of the Asian-Pacific region, InnoPack China has been paying close attention to demand changes of pharmaceutical and health product manufacturers in recent years. It has launched a series of professional activities while constantly improving and expanding its scope of exhibits in a pertinent manner, including “The International Summit for Pharmaceutical Packaging & Drug Delivery System”, “Innovation Gallery”, and “Explore Innovative Products Journey”, etc. The exhibition helps exhibitors receive attention from professionals from the pharmaceutical, food, health product, and other relevant industry fields, through a combination of diverse display channels. In recent years, more and more manufacturers of packaging design as well as drug delivery devices represented by inhalation drug delivery devices, prefilled syringes, injectors, transdermal drug delivery systems, and drug delivery device accessories, etc. have chosen to join InnoPack China, in addition to packaging material manufacturers.
Innopack China 2018
In 2018, in order to meet the rapid development of the pharmaceutical packaging industry and the growing of InnoPack China, the exhibition was relocated to Hall N5, which has a bigger exhibition area, and added temporary exhibition halls with an area of nearly 1,000m2, to largely increase the exhibition area. This was highly praised by all the exhibitors and visitors. New and regular exhibitors have actively responded since the exhibition registration of 2019 started. As of the middle of September 2018, over 150 quality suppliers including West, Sanner, Schott, GS, Nine Stars, Honeywell, UPM Raflatac, Klöckner Pentaplast, Global Printing, and Corning, etc. have confirmed their participation. Predictably, the exhibition scale and number of exhibitors will rise again to break the record in 2019.
Exhibitor Profile & Top Brands
Drug Delivery System
Flexible Packaging
Capsule
Printing Labels
Medicinal Hose
Plastic
Composite Materials
Atomizing Pump
Aluminum Foil
Plastic Cap Plug for Aluminium
Gasket
Medicinal Glass Bottles
Infusion Packaging
Prefilled Syringe
Top Brands
Proportion of European and American visitors grows year by year;an excellent international stage is built through quality
In addition to expanding the zone scale every year and building Chinese packaging enterprises a platform to compete with advanced products and design philosophies of Europe and America, InnoPack China also has effectively strengthened the brand influence among global pharmaceutical researchers and purchasers through measures such as increasing the proportion of international exhibiting brands, controlling quality of exhibitors and exhibits, integrating overseas media and association resources, and strengthening cooperation with the well-known European packaging exhibition Pharmapack.
The visits by overseas visitors in InnoPack China and the concurrent P-MEC & CPhI China reached 15,329 in 2018, wherein, the visits from European and American high-end markets, etc. grew by 67.7% over 2017. Overseas visits are expected to continue to grow in 2019 by over 20%, which will further consolidate the international status and influence of InnoPack China in the packaging industry.
PETALING JAYA, Malaysia, Nov. 26, 2018 /PRNewswire/ — MDT Innovations today reveals that it’s UHF RFID Linen Tags, Mi-LINOTAG 330 have been successfully tested at a world renowned magnetic resonance imaging (MRI) testing facility. The tests were conducted at Shellock R & D Services, Inc./Magnetic Resonance Safety Testing Services (http://www.magneticresonancesafetytesting.com) and it has validated that LINOTAG is suitable, safe and in compliance for usage under 1.5-Tesla and 3-Tesla MRI environments.
The Mi-Linotag 330 UHF RFID Linen Tags are sewn onto Linens such as uniform, blankets, kids surgical gowns, bedsheets and many more
MDT Innovations had specifically requested samples to be subjected to an extended period of one hour exposure under 3-Tesla MR scanner and the results were satisfactory. The tests were supervised by Dr. Frank G. Shellock and LINOTAGpassed both the test on the effects of worst-case MRI exposures, as well as possible MRI-related issues such as magnetic field Interactions, heating, and artifacts using its sophisticated techniques. Based on the results, Shellock R & D Services, Inc. recommended the designation of labeling to be “MR Conditional at 1.5- and 3-Tesla.” Notably, this is the one of the highest ratings that can be applied for an RFID device.
“We were impressed with the findings obtained from our tests that were applied on MDT Innovations’ LINOTAGS,” stated Dr. Frank G. Shellock, Adjunct Clinical Professor of Radiology and Medicine, Keck School of Medicine, University of Southern California. “Furthermore, we were satisfied to observe the relatively small image artifact generated by this particular RFID tag. The measured maximum image artifact size of 2 millimeters under severe MRI conditions will result in little or no impact on the diagnostic use of MRI.”
LINOTAG can be used in various applications, including healthcare industry (hospital linens), hospitality industry (hotel linens), and apparel retail industry. The LINOTAG is a passive RFID Tag with 96.3% made of linen including its yarn based wireless antenna. The LINOTAG has passed the needle detector test that make it highly suitable to be embedded during garment manufacturing processes. The reading distance is approximately 11 meters (on air) and it is suitable to be used as a laundry tag with sustainable environment up to 250 degrees Celsius and 60 bar pressure.
The LINOTAG has been introduced as a part of RAPITA® Connected Healthcare Services and was recently adopted by a Malaysian private hospital. The solution manages linen inventory and lifecycle such as procurement, daily usage, laundry, and disposals. It comes with extensive reports and active-dashboard system especially on distribution of linens, issuing soiled laundry, and receiving cleaned laundry. The provisional results obtained show that the solution cut down more than 30% of linen losses for this particular hospital.
About MDT Innovations
MDT Innovations is one of the fastest growing technology companies in Asia Pacific. Focusing on IoT (Internet of Things) value chains ranging from intelligent wireless communications, IoT as a services, to neural network solutions, the company offers services in the key domains such as crowd movement, things management and fintech enablement. MDT Innovations is proud of its standout engineering achievements mainly the development of world smallest NFC module, MD770R; NFC in SIM card, which shrunk RF front end and antenna into the size of SIM card; and Linotag which adopted yarn-based antenna in RFID tag.
The immense excitements of IoT and Industry 4.0 mega trends has further put MDT Innovations in the spotlights. MDT Innovations’ solutions in crowd movement, work in progress automation, and smart retail solutions are based on its intelligent wireless sensor systems. These solutions are found in Fortune-500 semiconductor firm and retail chains in China, Malaysia, and Australia.
The company has been profitable since its inception in 2004. MDT Innovations has seen tremendous growth especially in export sales and has grossed more than half a billion of accumulated export sales to date. As of 2017, 98.5% of total revenues are contributed by export sales, which is an evidence that the company has made successful international presence.
MDT Innovations is a multiple Asia Pacific ICT Award winner in 2006, 2007, 2013, 2017 and it is also the winner of Best of the Best, The Prime Minister Award in 2007 and 2013. The company is also Red Herring Asia 100 and Red Herring Global 100 in 2008 awarded by Red Herring Magazine, acknowledging 100 most innovative and promising technology companies of that year. This recognition put MDT Innovations amongst past winners like Google, Yahoo!, YouTube, Qualcom, and Ebay. In 2011, MDT Innovations adds Deloitte Technology Fast 500 Asia Pacific in 2011 to its list of accolades and it is ranked 12th. It is also Malaysia’s fastest growing company with 3130% from 2008 to 2010. Gartner also named MDT Innovations as cool vendor in 2015 and APAC CIO Magazine rated MDT Innovations among top 25 IoT solution providers in 2018.
Samsung has applied its AI algorithms to assist diagnosis in each of its imaging modalities.
CHICAGO, Nov. 26, 2018 /PRNewswire/ — Samsung Electronics, a leader in medical imaging technology, is showcasing its latest Ultrasound, Digital Radiography, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) concept and their software innovations at the Radiological Society of North America (RSNA) 2018 Annual Meeting at McCormick Place in Chicago.
Samsung AI presentation offering a glimpse of the recent endeavors in AI-based diagnostic
Samsung showcases their latest AI-based diagnostic imaging software at RSNA 2018
“We are pleased that Samsung’s AI technologies have been successfully applied to the existing diagnostic imaging devices and have been well received in the market,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “As a comprehensive diagnostic imaging solution provider, we will continue to strengthen our technologies through collaboration with hospitals and healthcare professionals. We aim to bring together radiologists and AI to fill in the gaps for improved healthcare management.”
Samsung showcases several types of AI based diagnostic imaging software:
Ultrasound System — S-Detect™ for Breast is AI based software which analyzes breast lesions using ultrasound images, and has been implemented into Samsung’s ultrasound systems dedicated to Radiology. It assists in standardizing reports and classification of suspicious breast lesions by incorporating BIRADS® ATLAS* (Breast Imaging-Reporting and Data System, Atlas)
According to a recently published study[1] by radiology professor Tommaso Bartolotta from the University of Palermo in Italy, S-Detect™ for Breast has shown to assist various degrees of improvement in the overall diagnosis of breast lesions. When using S-Detect™ for Breast, the diagnostic accuracy for doctors with experience of four years or less improved from 0.83 to 0.87 (AUC, Area Under Curve). S-Detect™ for Breast could be a useful tool for supporting and guiding breast diagnosis among non-expert breast imaging physicians (Only shape and orientation descriptors are automatically classified in the United States).
Digital Radiography — By using AI technology, the ‘Bone Suppression’ function, which reduces the bone signal from the chest x-ray image, clearly brings out the lung tissues obscured by the bones. ‘SimGrid™’ has also been introduced as a solution to ease the workflow to replace grids, while providing excellent image quality with reduced scatter artifacts. According to a recently published study[2], ‘SimGrid™’ provided image quality almost as good as the images taken with a physical grid.
The Auto Lung Nodule Detection (ALND) is a CAD (Computer Aided Detection) solution based on AI technology used in the detection of lung nodules and is 510(k) pending. According to a recent study[3] in press in Journal of Thoracic Imaging, ALND improved the detection sensitivity of lung cancer nodules 3 cm or smaller in chest radiographs by seven percentage points to 92 percent, compared with the average of six chest radiologists.
Computed Tomography — Samsung has introduced the intra-cranial hemorrhage package that combines a mobile stroke unit with a radiological computer aided triage and notification solution based on AI technology.
Magnetic Resonance Imaging — Utilizing AI technology, Samsung is developing a technology to display information such as knee cartilage thickness as well as images of knee arthritis patients. The software is a prototype and not for sale in any region of the world.
At the Samsung booth, attendees will find a separate ‘AI zone’ that allows visitors to experience Samsung’s AI technology more easily. Samsung will also host a symposium that will demonstrate how its image processing technology improves diagnostic accuracy and promote radiation safety for pediatric patients.
Through the release of new diagnostic tools that utilize diverse data based on AI technology, Samsung will continue to support healthcare professionals to improve the diagnostic accuracy.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
About Samsung Medison
Samsung Medison is a global leading medical device company, founded in 1985. With a mission to bring health and well-being of people’s lives, the company manufactures diagnostic ultrasound systems around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating world’s best IT, image processing, semiconductor and communication technologies into medical devices.
[1]
Tommaso Vincenzo Bartolotta, et al. Focal breast lesion characterization according to the BI-RADS US lexicon: role of a computer-aided decision-making support. La radiologia medica. 2018 Mar 22
[2]
S. Y. Ahn, et al. The Potential Role of Grid-Like Software in Bedside Chest Radiography in Improving Image Quality and Dose Reduction: An Observer Preference Study. Korean J Radiol, 2018; 19(3):526-533
[3]
M.J. Cha, et al. Performance of Deep Learning Model in Detecting Operable Lung Cancer with Chest Radiographs. J Thorac Imaging, 2018 In press
Mum of two from Australia has taken her popular silk bedding company international, offering American parents a solution to baby baldness and knotted hair
MELBOURNE, Australia, Nov. 21, 2018 /PRNewswire/ — Today, Australian-born online store Silky Tots officially launches its U.S platform. Silky Tots make a beautiful range of luxe silk bedding for babies and young children that are not your average sheets and pillow cases. Its world‘s first ‘cot slips’ help to prevent baby baldness and regrow lost hair. International expansion comes earlier than expected for the small startup but was considered necessary with an overwhelming amount of American parents requesting the bedding to be available overseas too.
Silky Tots was founded by mum of two, Nikki Bardis, after she kept finding clumps of hair in her daughters cot when she woke from sleep. Bardis came up with the idea of using high quality silk to stop this problem when she remembered that her Gran always used a silk pillowcase to protect her hair. Bardis immediately saw that and her daughter was no longer losing hair and was even regrowing hair on her bald patch. Online research found that there was no safe option available for purchase so Bardis applied her business knowledge gained from running other ecommerce stores and entrepreneur flare for textiles and design to create the silk range of bedding.
All products within the range have been designed in line with the SIDS safety guidelines, fitting snug over a normal cot sheet to create a silky barrier between the babies head and the sheet below. Interestingly, silk also has a number of extra benefits in addition to helping stimulate hair growth. It’s naturally hypoallergenic, helping soothe sensitive skin. It’s a dust mite repellent to make breathing crisper and cleaner for asthma sufferers and also temperature regulating so babies will stay cool in summer and warm in winter.
Ten weeks after launching the company in May 2018, Silky Tots was sold out of stock and saw financial profits in the hundreds of thousands. Sales can be attributed to the engaging social media channels hosted by the company with the majority of sales coming through Instagram. It was via social media that parents from the other countries, particularly the U.K and U.S, contacted Silky Tots and requested the products in their countries. Today, Silky Tots celebrates its first expansion with the rest of the world in its sights.
“We are so excited and proud to be expanding Silky Tots internationally after only launching the entire company 6 months ago,” says Bardis. “We know that parents are always looking for new products and services to better their children’s lifestyle. The bedding we’ve made offers a solution to balding and those who have matted, unmanageable hair. Making sure our kids are comfy when they’re sleeping is key and the results and feedback show that our young ones are sleeping like angels.”
American consumers can purchase the silk cot slips, bassinet slips, pillowcases and head support pillows at www.silkytots.com and can see the amazing results of children who have used the product on Instagram by visiting @silkytots or searching #bubwokeuplikethis.
For all media inquiries, please contact:
Kate Franich Director | Kick Off Communications M: +61-499-302-033 E: kate@kickoffcomms.com
LANGFANG, China, Nov. 22, 2018 /PRNewswire/ — On November 21, 2018, the licensing ceremony of “Change Training Camp” – the offline event of Change Your Life program of Jiangsu TV was held at Seven Cultivation Academy. ENNOVA Seven Cultivation Academy was officially licensed as the Only Designated Partner of Change Training Camp of the TV program. The ceremony was attended by Wu Hongmei, the program producer, Mr. Liu Zhengju, VIP guest of the TV program, Mr. Mu Yiming, Chief Physician of the Endocrinology Department at 301 Hospital and expert tutor of Change Your Life, Ms. Zhang Lina, General Manager of ENNOVA Health, Ms. Zhang Xinglan, Vice General Manager and Chairman of Seven Cultivation Academy and many media partners.
ENNOVA Seven Cultivation Academy Licensed by JSTV “Change Your Life”
The first reality show led by top medical experts, Change Your Life has been airing at 22:00 each Saturday since November 24 on Jiangsu TV (JSTV).
On the same day of the licensing ceremony, ENNOVA Seven Cultivation launched three required courses for body-shaping and mind-cultivating, “Weight Reducing and Meditation Camp”, “Seven Cultivation Burden Alleviation Camp” and “Seven Cultivation Physical & Mental Reshaping Camp”. The “Seven Cultivation Health Supervisors” will help overweight students learn the Seven Cultivation of “cultivation of virtues, food nourishment, practicing traditional martial arts, learning calligraphy, studying aromatherapy, appreciating ancient court music and flower art” and lead a lifestyle that truly conforms to modern health standards.
Given the fact that “puts the public health in the strategic place of prioritized development” and the concept that “prosperity for all is impossible without health for all”, ENNOVA Health carries forward the mission of “reduce diseases of all people as far as possible”, actively explores life sciences and safeguards human health and life. ENNOVA Seven Cultivation continuously advocates and implements the advanced philosophy of a healthy lifestyle. “I believe that the training camp of Change YourLife will substantially cultivate a healthy lifestyle integrating dual virtues and fun through the cultivation of virtues, food nourishment, practicing traditional martial arts, learning calligraphy, studying aromatherapy, appreciating ancient court music and flower art,” said ENNOVA Health General Manager Ms. Zhang Lina.
SHANGHAI, Nov. 22, 2018 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced in the district of Fengxian in Shanghai.
The new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists.
“The commencement of this new biologics center will further expand WuXi Biologics’ unparalleled capacities and we are glad to witness its construction today. WuXi Biologics is committed to developing and manufacturing biologics more cost effectively as well as to providing a robust supply chain network for our global partners to benefit patients worldwide,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
BEIJING, Nov. 23, 2018 /PRNewswire/ — Entrepreneur of the Year, one of the most highly regarded awards in innovation, was announced at the Annual Entrepreneurs Meeting held in Beijing today. With innovative achievements in healthcare sector, Mr. Wang Tao, Chairman and CEO of Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, stock code: 01833.HK) stands out from hundreds of candidates and was awarded the “2018 Top Ten Entrepreneur of the Year” by Dark Horse Venture Technology, becoming the only entrepreneur in the healthcare sector to receive the honor this year.
He Li (left), Co-founder of Jiemian News and Vice Chairman of Jiemian Cailianshe, awarded the “2018 Top Ten Entrepreneur of the Year” to Wang Tao (right), Chairman and CEO of Ping An Good Doctor
The “Top Ten Entrepreneurs” candidates are selected by the media, previous annual entrepreneurs, investors, and the Dark Horse community. The professional jury is composed of famous angel investors, venture capital investors, business leaders, business school professors and journalists. The final ten nominees represent the most powerful transformation force in their industries, making the award highly regarded in the community.
Mr. Niu Wenwen, the Founder and Chairman of Dark Horse Venture Technology, said “Mr. Wang Tao is a great navigator in Internet healthcare field. With the insights, user advantages and ‘Internet + AI’ technology, he led Ping An Good Doctor to provide convenient and quality one-stop medical healthcare service for hundreds of millions of users. He led the company to be the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange in May this year.”
At the Meeting, Mr. Wang also delivered a keynote speech entitled “Technology Makes People Healthier”. He said: “The original intention of establishing Ping An Good Doctor is to leverage Internet and AI technology to make people more convenient when consulting the doctor, as well as providing patients with easy access to quality medical resources.”
Wang Tao, Chairman and CEO of Ping An Good Doctor
When talking about the current China medical and healthcare market, Mr. Wang summed up three long-standing pain points: lack and unevenly distribution of high-quality medical resources, poor medical service experience, and social security funds are gradually unable to make ends meet. “Generally, we now think that it is difficult to have medical consultation and the medical cost is expensive. The most important reason is those Class III Grade A hospitals account for only 8% of the total number of hospitals in China but must accept more than 50% of the patients. Everyone wants to see a good doctor, so the major Class III Grade A hospitals are overcrowded. Data shows that at present, the average queuing time for domestic medical treatment is as high as three hours, and the average consultation time is less than eight minutes,” he said.
However, Mr. Wang believes that China’s medical and healthcare market has great potential for development. It is estimated that the potential value for China’s medical and healthcare will total RMB8 trillion by 2025, of which the potential transaction volume of Internet healthcare will exceed RMB100 billion. Domestic and international favorable policies for Internet medical treatment have also been promulgated continuously, which has played a positive role in propelling the market development.
Both challenges and opportunities rise from difficulties. Under the leadership of Mr. Wang, Ping An Good Doctor has become the largest unicorn company in the global medical and healthcare field in just over three years. It has built four core strengths in the industry including an in-house medical team of more than a thousand medical personnel, the world’s leading AI medical technology, massive healthcare users and healthcare big data.
“Everyone wants to enjoy the best medical resources, but where do they come from? It is certainly not possible in the traditional way, and it is impossible to have enough finances, material and time to solve the problem. We will use AI technology to find a solution to the problem of the shortage of good doctors in China.” Mr. Wang believes that with the big data of more than 300 million online consultations accumulated by an in-house medical team of more than thousand medical personnel, plus more than 200 of the world’s top AI experts, Ping An Good Doctor has developed the most advanced AI Doctor in the medical profession. It can reduce the misdiagnosis rate of traditional medical care, improve the efficiency of medical resources, accurately match the needs of doctors and patients, and simplify the doctor’s workflow.
At present, AI Doctor has already entered The People’s Liberation Army No. 303 Hospital, Qingdao Eye Hospital, The First Affiliated Hospital of Jinan University, The Third Affiliated Hospital of Southern Medical University, and over 100 Class III Grade A hospitals nationwide, multiplying the efficiency and accuracy of hospitals and reducing operating costs. In addition, AI Doctor technology has entered Traditional Chinese Medicine (TCM), corresponding to the Chinese medicine consultation process of “observation, listen to breathing, ask about symptoms and pulse-taking”. It can simulate TCM medicine practitioners to conduct inquiries before diagnosis, and through comprehensive analysis and inferential diagnosis, generate and transmit the analysis results to the doctor’s workbench, intelligently recommend Chinese medicine prescriptions for doctors to choose, and effectively improve the patient experience.
“China’s best medical resources are often gather in the first-tier cities such as Beijing, Shanghai and Guangzhou, while many county-level cities and mountainous areas suffer from a lack of medical resources. It is very painful for people to travel a long way for seeing a doctor. Now, we expect to solve the dilemma of uneven distribution of medical resources by using internet technology. This will help patients in small towns such as Guizhou could enjoy the same medical resources as well as those who live in Xujiahui District of Shanghai.” Mr. Wang said.
Finally, Mr. Wang believed that the three major problems in China’s healthcare market also exist in the overseas markets. Therefore, Ping An Good Doctor is proactively promoting its internationalization strategy, exporting its mature technologies and services to overseas markets, and coordinating medical resources around the world to create the world’s largest healthcare ecosystem. It aims to use technology to make people healthier.
About Ping An Healthcare and Technology Company Limited (01833.HK)
Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, stock code: 01833.HK) is the leading one-stop healthcare ecosystem platform in China. By combining “mobile health + AI technology”, the Company strives to provide every family with a family doctor, every person with an e-health profile and everyone with a healthcare management plan. Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem covering family doctor services, consumer healthcare services, a health mall as well as health management and wellness interaction.
As of the end of June 2018, there were 228 million registered users and the Company’s MAU reached 48.6 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale. Ping An Good Doctor employs more than a thousand medical personnel (Assistant Supervisor Level or above from Class III Grade A Hospitals) in its in-house medical team and contracts with 4,650 renowned external doctors. This in-house medical team, empowered by our proprietary AI technology, provides users with 24 x 7 online consultation services. In our offline partnership network, Ping An Good Doctor collaborates with approximately 3,100 hospitals (including more than 1,200 Class III Grade A hospitals) to provide services such as hospital referral, appointment and inpatient arrangements. Ping An Good Doctor also partners with more than 2,000 healthcare institutions, including physical examination centers, dental clinics, cosmetic surgery institutions and more than 10,000 pharmacy outlets, to provide relevant health and wellness services to our users. By integrating our AI-empowered medical team, external doctors and offline network, Ping An Good Doctor has established a closed-loop healthcare ecosystem which enables our users to enjoy online consultations and online drug purchases, as well as online consultations and offline follow-up treatment, thereby providing convenient, high-quality and efficient family doctor services.
In April 2015, the App “Ping An Good Doctor” was officially launched. In May 2016, the Company completed an A round financing and raised US$500 million. In December 2017, the Company completed the pre-IPO financing from Softbank Vision Fund, during which it raised US$400 million. On 4 May 2018, Ping An Good Doctor became the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange, stock code 01833.HK. Our IPO cornerstone investors include Blackrock, Capital Group, GIC, Canada Pension Plan Investment Board, Khazanah Nasional Berhad, Swiss Re and CP Group.
